Unravelling G protein‐coupled receptor signalling networks using global phosphoproteomics

Pokhrel, Rina; Morgan, Alexandra; Robinson, Harley; Stone, Martin J.; Foster, Simon R.

doi:10.1111/bph.16052

Cited by 2 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given that platelets lack nuclei and are incapable of initiating large-scale transcriptional changes [44,45], transcriptomics technologies were deemed unsuitable for investigating the signal transduction in platelets. Instead, mass spectrometry-based phosphoproteomics technologies, known for their efficacy in studying various cellular processes, signal transductions, and enzyme activity modulations [46][47][48], were employed. We leveraged phosphoproteomics technologies to scrutinize the instantaneous post-translational modifications and signal transduction cascades during platelet activation and inhibition [49].…”

Section: Reciprocal Regulations Of Phosphoproteinsmentioning

confidence: 99%

Novel regulators identified by quantitative phosphoproteomics analysis during ticagrelor-induced inhibition of platelet

Song,

Xu,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

Purpose: To study the antiplatelet mechanisms of ticagrelor. Experimental design: Platelets underwent activation with 20 μM ADP for 30 seconds followed by inhibition with 2 nM ticagrelor for another 30 seconds. Mass-spectrometry-based phosphoproteomic technique was applied to obtain phosphorylation spectra in platelets. Results: We successfully quantified 2285 phosphopeptides with high confidence in 1189 phosphoproteins. Compared with intact platelets, ADP-activated platelets showed significant upregulation of PDE5ASer102 and downregulation of 178 phosphopeptides in 154 proteins. Gene Ontology analysis showed that downregulated phosphoproteins were enriched in molecular functions and pathways associated with RNA processing and surveillance. After ticagrelor treatment, we identified 53 significantly regulated phosphopeptides, including 17 upregulated and 36 downregulated, in 45 phosphoproteins. Eight phosphopeptides in STIM1, DENND4C, TNIK, BCL9L, DBN1, DOCK10, FRMD4B, and PRKAR2B were significantly downregulated after ADP stimulation and significantly upregulated after adding ticagrelor. They were mainly implicated in regulation of Ca2+ flow, Wnt/β-catenin signaling, and cytoskeleton remodeling, suggesting their potential role as mediators in ticagrelor-related signaling pathways. Conclusions and clinical relevance: By sequential activation and inhibition of platelets using mutual competitive inhibitors, ADP and ticagrelor, we demonstrated alternations in phosphorylation status of phosphoproteins, which could help to interpret the mechanism of bleeding complications associated with ticagrelor.

show abstract

Section: Reciprocal Regulations Of Phosphoproteinsmentioning

confidence: 99%

Novel regulators identified by quantitative phosphoproteomics analysis during ticagrelor-induced inhibition of platelet

Song,

Xu,

Yang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Methodological advances in phosphoproteomics are also making an impact, where advances to automated workflows, phosphopeptide mapping, and instrumentation enable highly sensitive unbiased discovery of systems‐level phosphorylation events that would otherwise not be detected. Pokhrel et al (2024) elegantly provide a stepwise approach to developing a phosphoproteomics workflow in the GPCR space. Finally, the rapid and powerful recent advances in artificial intelligence, particularly in machine learning and deep learning, are highlighted as an opportunity for ‘faster, smarter and cheaper’ drug discovery by Nguyen et al (2024).…”

mentioning

confidence: 99%